These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 23088608)
1. Target Selectivity of FimH Antagonists. Scharenberg M; Schwardt O; Rabbani S; Ernst B J Med Chem; 2012 Nov; 55(22):9810-6. PubMed ID: 23088608 [TBL] [Abstract][Full Text] [Related]
2. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. Klein T; Abgottspon D; Wittwer M; Rabbani S; Herold J; Jiang X; Kleeb S; Lüthi C; Scharenberg M; Bezençon J; Gubler E; Pang L; Smiesko M; Cutting B; Schwardt O; Ernst B J Med Chem; 2010 Dec; 53(24):8627-41. PubMed ID: 21105658 [TBL] [Abstract][Full Text] [Related]
3. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Schwardt O; Rabbani S; Hartmann M; Abgottspon D; Wittwer M; Kleeb S; Zalewski A; Smieško M; Cutting B; Ernst B Bioorg Med Chem; 2011 Nov; 19(21):6454-73. PubMed ID: 21962988 [TBL] [Abstract][Full Text] [Related]
5. FimH antagonists: structure-activity and structure-property relationships for biphenyl α-D-mannopyranosides. Pang L; Kleeb S; Lemme K; Rabbani S; Scharenberg M; Zalewski A; Schädler F; Schwardt O; Ernst B ChemMedChem; 2012 Aug; 7(8):1404-22. PubMed ID: 22644941 [TBL] [Abstract][Full Text] [Related]
6. A flow cytometry-based assay for screening FimH antagonists. Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870 [TBL] [Abstract][Full Text] [Related]
7. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Mydock-McGrane LK; Hannan TJ; Janetka JW Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090 [TBL] [Abstract][Full Text] [Related]
8. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. Kleeb S; Pang L; Mayer K; Eris D; Sigl A; Preston RC; Zihlmann P; Sharpe T; Jakob RP; Abgottspon D; Hutter AS; Scharenberg M; Jiang X; Navarra G; Rabbani S; Smiesko M; Lüdin N; Bezençon J; Schwardt O; Maier T; Ernst B J Med Chem; 2015 Mar; 58(5):2221-39. PubMed ID: 25666045 [TBL] [Abstract][Full Text] [Related]
9. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660 [TBL] [Abstract][Full Text] [Related]
10. Kinetic properties of carbohydrate-lectin interactions: FimH antagonists. Scharenberg M; Jiang X; Pang L; Navarra G; Rabbani S; Binder F; Schwardt O; Ernst B ChemMedChem; 2014 Jan; 9(1):78-83. PubMed ID: 24357503 [TBL] [Abstract][Full Text] [Related]
11. The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH. Wellens A; Lahmann M; Touaibia M; Vaucher J; Oscarson S; Roy R; Remaut H; Bouckaert J Biochemistry; 2012 Jun; 51(24):4790-9. PubMed ID: 22657089 [TBL] [Abstract][Full Text] [Related]
12. Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. Jiang X; Abgottspon D; Kleeb S; Rabbani S; Scharenberg M; Wittwer M; Haug M; Schwardt O; Ernst B J Med Chem; 2012 May; 55(10):4700-13. PubMed ID: 22519985 [TBL] [Abstract][Full Text] [Related]